Update to Abrysvo and Arexvy for the 2025-2026 RSV Prevention Program

This memo follows our September 10, 2025 communication regarding the RSV Prevention Program. As the fall respiratory season begins, Hamilton Public Health continues to review the allocation of doses received from the Ministry and compare this supply against the needs of Hamilton residents. 

At this time, due to limited supply, Abrysvo will only be released to Health Care Providers for administration to pregnant individuals. 

We are asking you to vaccinate eligible individuals aged 60+ exclusively with Arexvy moving forward. 

Eligibility for Abrysvo and Arexvy will be the following:

Abrysvo

• pregnant persons between 32-36 weeks gestation who will deliver during the RSV season, following a discussion with a health care provider.
  • Reminder: Administration of both the vaccine to the pregnant individual and monoclonal antibody to the infant is not needed except under specific circumstances:
    • Infants born less than 14 days after administration of Abrysvo OR
    • Infants who meet the medical criteria for increased risk of severe RSV disease:
      • All premature infants (i.e., <37 weeks gestation)
      • Infants who meet any of the above high-risk criteria

Arexvy

• all individuals aged 75 and older (new for the 2025-26 season)
• individuals 60 to 74 years of age who are also:
  • residents of long-term care homes, Elder Care Lodges, or retirement homes including similar settings (e.g., co-located facilities).
  • patients in hospital receiving alternate level of care (ALC) including similar settings (for example, complex continuing care, hospital transitional programs)
  • patients with glomerulonephritis (GN) who are moderately to severely immunocompromised.
  • patients receiving hemodialysis or peritoneal dialysis.
  • recipients of solid organ or hematopoietic stem cell transplants.
  • individuals experiencing homelessness.
  • individuals who identify as First Nations, Inuit, or Metis.

As a reminder, if an individual has previously received a dose of RSV vaccine, they do not need to receive another dose this season, as booster doses are not currently recommended. 

To place an order, please complete the attached order form and submit by email to [email protected] or by fax to 905-546-3472. 

When ordering, please allow 24-48 hours for processing and ensure that you attach 4 weeks of refrigerator temperatures.

Medical Memo & Order Form

Update to Abrysvo and Arexvy for the 2025-2026 RSV Prevention Program(PDF, 214.73 KB)